Leerink Partnrs Decreases Earnings Estimates for AnaptysBio

AnaptysBio, Inc. (NASDAQ:ANAB) – Equities research analysts at Leerink Partnrs dropped their Q3 2025 EPS estimates for shares of AnaptysBio in a report issued on Tuesday, September 30th. Leerink Partnrs analyst D. Risinger now forecasts that the biotechnology company will post earnings per share of ($0.85) for the quarter, down from their prior forecast of ($0.84). The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. Leerink Partnrs also issued estimates for AnaptysBio’s Q4 2025 earnings at $1.04 EPS, FY2025 earnings at ($1.69) EPS, FY2026 earnings at ($2.98) EPS, FY2027 earnings at ($3.01) EPS, FY2028 earnings at ($1.87) EPS and FY2029 earnings at ($0.82) EPS.

A number of other equities research analysts have also recently weighed in on the company. Wedbush restated an “outperform” rating and issued a $45.00 price target on shares of AnaptysBio in a research note on Tuesday. JPMorgan Chase & Co. lifted their target price on shares of AnaptysBio from $42.00 to $80.00 and gave the stock an “overweight” rating in a report on Thursday, July 24th. HC Wainwright raised their price objective on shares of AnaptysBio from $38.00 to $59.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, UBS Group restated a “neutral” rating and issued a $20.00 price target (up from $18.00) on shares of AnaptysBio in a research note on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $48.75.

AnaptysBio Stock Down 2.0%

ANAB opened at $31.34 on Friday. AnaptysBio has a 12-month low of $12.21 and a 12-month high of $36.54. The business has a 50 day moving average of $22.34 and a 200-day moving average of $21.74. The stock has a market cap of $877.52 million, a price-to-earnings ratio of -7.00 and a beta of -0.18.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.16. The company had revenue of $22.26 million for the quarter, compared to analysts’ expectations of $11.55 million. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%.

Institutional Investors Weigh In On AnaptysBio

A number of hedge funds have recently made changes to their positions in ANAB. US Bancorp DE increased its holdings in shares of AnaptysBio by 126.5% during the first quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock worth $33,000 after buying an additional 979 shares in the last quarter. Farther Finance Advisors LLC increased its stake in shares of AnaptysBio by 9,778.9% in the first quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 1,858 shares during the period. Tower Research Capital LLC TRC raised its holdings in AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,377 shares during the last quarter. Osaic Holdings Inc. boosted its position in AnaptysBio by 11,630.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after buying an additional 2,326 shares during the period. Finally, GAMMA Investing LLC bought a new stake in AnaptysBio during the 1st quarter worth approximately $113,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.